Navigation Links
Researchers develop device that simulates gastro-intestinal tract
Date:3/31/2014

A breakthrough in drug testing developed by a University of Huddersfield lecturer could lead to cheaper, more effective medicines. Dr Hamid Merchant is a member of the team that has created a device which accurately simulates the gastro-intestinal tract and how it absorbs medication. This means that the cost of clinical trials could be greatly reduced, with savings passed on to customers.

Dr Merchant has joined the University as a Senior Lecturer in Pharmaceutics. Previously a postdoctoral fellow at University College London (UCL), he has extensive research experience, with a speciality in drug delivery and formulations. He has published regularly in peer-reviewed journals and made presentations to prestigious bodies that include the American Association of Pharmaceutical Scientists, to whom he has described his work in developing the apparatus for testing the solubility of medicines in their annual meeting and exposition in November 2013 at St Antonio (Links to abstracts... AAPS 2013-R6065, AAPS 2013-T3050, AAPS 2013-W5338, AAPS 2013-T3119, AAPS 2013-R6310).

The device is the subject of a patent application with potential commercial partners already expressing interest and a working prototype has been constructed at UCL. It has already been used, under contract, by drug companies in order to test new products. Dr Merchant now aims to establish a second prototype at the University of Huddersfield.

Dr Merchant explained that the cycle for developing and delivering a new drug involves pre-clinical tests on animals. If these are deemed safe and satisfactory, clinical trials on humans can then begin. But differences between animal and human gastrointestinal tracts mean that the pre-clinical tests do not always provide sufficiently reliable information about drug absorption from differing formulations. This has to be investigated at considerable expense during the clinical trial phase.

Therefore, Dr Merchant and his colleagues developed a laboratory device that simulates the human gut and its differing pH gradients, which play a decisive role in determining the manner, in which orally-administered medications are dissolved and then absorbed. It is now possible to fairly discriminate the formulations of a new drug and identify potential candidates for further development that are likely to be successful during clinical trials.

"By minimising human trials we would reduce the cost of development, which is then charged to patients when the drug comes to the market if the development costs are lower, then we can make new drugs more affordable," said Dr Merchant, who has research experience in industry as well as academia.

The testing device, co-developed by Dr Merchant, includes a chamber for holding a solvent medium plus a pH probe and a control unit. This monitors changes in the pH of the solvent medium in order to test the performance of a drug carrier at different levels of acidity or alkalinity, mimicking the conditions of the gastrointestinal tract. The device is particularly suitable for testing and developing dosage forms for oral delivery of drugs and can also simulate the variability between individuals.


'/>"/>

Contact: Nicola Werritt
nicola.werritt@hud.ac.uk
01-484-473-315
University of Huddersfield
Source:Eurekalert  

Related medicine news :

1. UNC researchers show cancer chemotherapy accelerates molecular aging
2. NUS researchers developed worlds first fluorescent sensor to detect date rape drug
3. Cancer researchers find key protein link
4. Researchers: Biomarkers predict effectiveness of radiation treatments for cancer
5. Researchers issue state-of-the-state on genetic-based testing and treatment for breast cancer
6. Researchers identify impaired new learning in persons with Parkinsons disease
7. Researchers identify potential new therapeutic target for controlling high blood sugar
8. Ottawa researchers find new pathway connected to type 2 diabetes
9. Shoulder revision repair surgery not as successful 2 years later, say researchers
10. Researchers find significant increase in painkillers prescribed to US adults in the ER
11. Dartmouth researchers develop new approach to chronic lymphocytic leukemia treatment
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Researchers develop device that simulates gastro-intestinal tract
(Date:3/23/2017)... ... March 23, 2017 , ... Michael Lanteri Agency, an insurance ... Collins area, has unveiled a collaboration with nonprofit Big Bones Canine Rescue as ... worthy cause may now be made at http://bigbonescaninerescue.com/ . , Big Bones ...
(Date:3/23/2017)... ... March 23, 2017 , ... Altec Products, Inc. , ... as their 2016 Microsoft Dynamics Partner of the Year at DocLink Evolution ... award recognizes The Resource Group for their outstanding relationship with Altec and their ...
(Date:3/23/2017)... ... March 23, 2017 , ... Sharon Kleyne, host of ... Change and Your Health on VoiceAmerica, recently talked on her program about how she ... the occasion to remind listeners of an important distinction. World Water Day, Kleyne pointed ...
(Date:3/23/2017)... Kennett Square, PA (PRWEB) , ... March 23, 2017 , ... ... sunny days. That means many students are thinking about summer internships , which ... (or lack thereof). , The pros at Garden Media Group, a boutique public relations ...
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... The American ... 2017 marks the 40th Anniversary of ABQAURP’s dedication to Health Care Quality and Management ... who have contributed not only to the association, but also to the Health Care ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... SILVER SPRING, Md. , March 23, 2017 /PRNewswire-USNewswire/ ... approval to Bavencio (avelumab) for the treatment of adults ... Merkel cell carcinoma (MCC), including those who have not ... for metastatic MCC, a rare, aggressive form of skin ... the most common cancers, patients with a rare form ...
(Date:3/23/2017)... VANCOUVER, British Columbia , March 23, 2017 ... (the "Company" or "Sophiris"), a clinical late-stage biopharmaceutical company ... today announced that data from its successful Phase 2a ... focal treatment for localized prostate cancer, will be presented ... 32 nd Annual European Association of Urology in ...
(Date:3/23/2017)... Research and Markets has announced the addition of the ... offering. ... global oxygen therapy devices market to grow at a CAGR of ... Oxygen Therapy Devices Market 2017-2021, has been prepared based on an ... the market landscape and its growth prospects over the coming years. ...
Breaking Medicine Technology: